17 results about "Colistin" patented technology

A polyclonal antibody composition specifically binds the pTonB epitope (SEQ ID NO: 11) from Acinetobacter baumannii and is elicited by immunization with a multi-epitope antigen comprising thioredoxin leader, rigid linker, and kernels including SEQ ID NOs: 6, 7, 11, 12, and 8. These antibodies enhance opsonophagocytic killing of A. baumannii Ci79 via classical complement activation and Fey receptor-mediated phagocytosis by bone marrow-derived macrophages. Absorption of pTonB-specific antibodies reduces killing by >70%, confirming epitope dominance. Passive transfer of the composition protects >60% of mice in a lethal intranasal challenge model. Pharmaceutical compositions, treatment methods (alone or with antibiotics like colistin), prophylactic uses, diagnostic kits, and polyclonal compositions are disclosed for combating multidrug-resistant A. baumannii infections.

The present invention relates to a method for treating Gram-negative bacteria that are resistant to colistin (MIC > 50 mg / mL), an antibacterial compound, excluding those of the genera Burkholderia, Proteus, and Serratia, comprising contacting the bacteria with an aqueous pharmaceutical composition containing a rose bengal (RB) compound of formula I, dissolved or dispersed at a concentration of about 0.01 to about 15 mg / mL, and irradiating the contacted bacteria with light of a wavelength of about 500 nm to about 600 nm for a period of about 1 to about 10 minutes, at a concentration of about 16 to about 160 J / cm². 2 The aim is to create a method that involves obtaining a certain amount of light to treat and kill irradiated bacteria. [Formula 1] JPEG2026511692000028.jpg5864 (where X, R 1 , R 2 (and M+ are defined herein)

Colistin is an important last-resort antibiotic, but its production involves significant challenges due to the presence of impurities resulting from various analogs and the limited number of native producers. In response, disclosed are mutant Paenibacillus bacteria that produce Colicin A more efficiently and / or Colicin A that is of higher purity and / or has a cleaner metabolite background. The disclosed mutant bacteria are genetically engineered to inactivate expression of one or more biosynthetic gene clusters (BGCs), increase expression of one or more other BCGs, and / or increase expression of one or more L-DABA pathway genes.

The application discloses application of BMS-833923 and derivatives thereof and a medicine, and belongs to the technical field of antibiotics. The BMS-833923 and the derivatives thereof can be used as colistin adjuvants to jointly inhibit or eliminate gram-negative bacteria, and can also independently inhibit or eliminate gram-positive bacteria. The gram-negative bacteria can include at least one of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, pan-drug-resistant strains BAA-1800, BAA-1794 and BAA-1792, and the gram-positive bacteria can include at least one of Staphylococcus aureus and Bacillus subtilis. By taking the BMS-833923 and the derivatives thereof as adjuvants of colistin, the therapeutic index of the colistin can be effectively expanded, and lower, non-toxic doses of the colistin can be used in clinical treatment of effective treatment of drug-resistant bacterial infections.

The invention discloses an application of liquiritigenin in preparation of a bactericide or an antibiotic synergist. The invention discloses the synergistic effect, the antibacterial property and the synergistic mechanism of liquiritigenin on colistin and the potential value of in-vivo combined application of liquiritigenin. On the basis, a feasible treatment scheme is provided to cope with the increasingly aggravated drug resistance problem, the use curative effect of the colistin is effectively enhanced, and the clinical service life of the colistin is prolonged. The possibility that liquiritigenin is used as a colistin synergist to resist infection of multi-drug-resistant pathogenic bacteria is reduced. The liquiritigenin can reduce the minimum inhibitory concentration of the colistin to drug-resistant gram-negative bacteria by 16 times, and the antibacterial activity of the colistin is greatly improved.

This invention relates to the field of biochemical technology, and particularly to highly specific haptens of polymyxin B and colistin, artificial antigens, their preparation methods, and applications. The haptens have structures as shown in Formula I or Formula II. The applications include: (1) preparing specific antibodies against polymyxin B or colistin; (2) detecting specific antibodies against polymyxin B or colistin; and (3) preparing reagents for detecting specific antibodies against polymyxin B or colistin. This invention further provides artificial antigens obtained by conjugating the haptens with carrier proteins. Using the artificial antigens provided by this invention as immunogens to immunize experimental animals, highly specific and sensitive antiserum can be prepared, which can then be used to extract and prepare polyclonal antibodies. These methods can be used to establish highly specific, highly sensitive, simple, and rapid detection methods for polymyxin B and colistin, and have significant application value.

The present invention relates to the synergic association of colistin and N-acetylcysteine (NAC) for the treatment and eradication of mature biofilm-associated infections by P. aeruginosa. In particular the synergic association of colistin and NAC is useful for the treatment and eradication of P. aeruginosa infections in patients suffering from chronic lung diseases and recurrent P. aeruginosa infections.

The present invention provides antibiotic combination therapies for treating Acinetobacter baumannii infection in a subject. These combination therapies comprise rifudine and a second antibiotic such as colistin and cefdinir.

Described herein are compositions, methods, and kits for detecting antibiotic resistance genes in a sample, such as a wound swab. One embodiment described herein is primer pairs and probes for individual or multiplex polymerase chain reaction (PCR) based assays for the detection of one or more antibiotic resistance gene targets comprising resistance to molecularly characterized extended-spectrum β-lactamases (MESBLs); extended-spectrum β-lactamases (ESBLs); carbapenemase; AmpC β-lactamase; β-lactamase; lincosamide, macrolide, streptogramin; trimethoprim; macrolides; methicillin; colistin; sulfonamide; tetracycline; vancomycin; nitroimidazole; quinolone; or aminoglycoside.

The present invention contemplates a method for treating gram-negative bacteria other than the genus Burkholderia, Proteus and Serratia, said gram-negative bacteria also exhibiting drug resistance (MIC > = 50 mg / mL) against the bacterial compound colistin, said gram-negative bacteria also exhibiting drug resistance (MIC > = 50 mg / mL) against the bacterial compound colistin, such as colistin, colistin, colistin, colistin, colistin, colistin, colistin, colistin, colistin, colistin, colistin, colistin and colistin. The method comprises contacting bacteria with an aqueous pharmaceutical composition containing a rose-bengal (RB) compound of the following formula I dissolved or dispersed therein at a concentration of from about 0.01 to about 15 mg / mL, and irradiating those contacted bacteria with light having a wavelength of from about 500 nm to about 600 nm for a period of from about 1 to about 10 minutes to provide a light dose of from about 16 to about 160 J / cm2, treating and killing the irradiated bacteria, wherein X, R1, R2 and M + are defined herein.

The invention relates to the technical field of biological medicine. The invention provides an application of Obtoclax mesylate and / or Nigericin in preparation of an antibiotic sensitizer, wherein the antibiotic comprises colistin. The invention also provides an application of Obtoclax mesylate and / or Nigericin in preparation of the antibiotic sensitizer. The invention further provides an application of the medicine composition of the colistin and the Obtoclax mesylate or the Nigericin in preparation of the medicine for resisting the colistin drug resistance gram-negative bacteria, and the medicine composition of the colistin and the Obtoclax mesylate or the Nigericin can be used for preparing the medicine. According to the technical scheme, the colistin and Obtoclax mesylate or Niguricin are combined for use, so that a synergistic effect is achieved, the MIC value of the colistin for resisting colistin-resistant gram-negative bacteria can be remarkably reduced, and the growth of the gram-negative bacteria is inhibited.

The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and / or treatment of bacterial infections and antibacterial-induced dysfunctions. The compositions of the present invention demonstrate high species-specificity in inhibiting the growth of a small number of bacterial species, and most importantly are effective also against multi drug resistant (MDR) clinical isolate species. Interestingly, one of those combinations pairs a non-antibiotic drug, vanillin, with an antibiotic drug, spectinomycin, to demonstrate a surprisingly strong inhibitory effect on the growth of clinically relevant Gram-negative pathogenic and multi-drug resistant E. coli isolates. A second set of compounds combines the polymyxin colistin with loperamide, a rifamycin, or a macrolide. Importantly, this invention relates to combinations that enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development efforts in order to prevent major side effects of antibacterial strategies. This invention also relates to pharmaceutical combinations useful to prevent an adverse effect on the gut microbiome, induced by the use of antibacterial compounds.

The present invention is directed to novel resistance modifying agents (RMAs) compounds configured to potentiate antibiotic compounds, such as polymyxin antibiotics, including colistin, directed to multi-drug resistance (MDR) gram-negative bacteria.

The application discloses application of sphingosine or its acceptable salt in preparation of a medicine or preparation for killing and / or inhibiting bacteria in and out of organisms. The application discloses application of sphingosine or its acceptable salt in preparation of a medicine for bacterial infectious diseases or preparation of an antibiotic synergist. The application discloses a medicine composition comprising sphingosine and colistin. The application discloses application of the composition in preparation of a medicine or preparation for killing and / or inhibiting bacteria in and out of organisms or preparation of a medicine for bacterial infectious diseases or an antibiotic synergist. The application finds the possibility of sphingosine as the colistin synergist for resisting multiple drug-resistant pathogenic bacterial infection through in-vivo and in-vitro antibacterial tests. The sphingosine can reduce the minimum inhibitory concentration of colistin to drug-resistant gram-negative bacteria by 30 times, greatly improving the antibacterial activity of colistin.

The application discloses a method for improving colistin E wastewater treatment capacity, and belongs to the technical field of wastewater treatment. Specifically, the method comprises the following steps: A, taking activated sludge and placing the activated sludge in a reactor; B, taking colistin E production wastewater with additional cyclic diguanidate, and making the colistin E production wastewater flow through the reactor at a certain organic load. The colistin E production wastewater has a toxic effect on the microorganisms in the activated sludge in many aspects, so that the growth of the microorganisms is inhibited. The cyclic diguanidate is a key regulating factor for synthesizing extracellular matrix, and it can activate a series of genes participating in the synthesis of components such as extracellular polysaccharide and protein, so that the microorganisms can produce a large amount of extracellular matrix. The extracellular matrix is a main component of a biofilm, and can provide protection and a stable living environment for the microorganisms. The experiment proves that the colistin E production wastewater with additional cyclic diguanidate can effectively improve the wastewater treatment capacity.

This invention discloses a fermented Sophora japonica flower extract for enhancing the efficacy of colistin, its preparation method, and its application. The preparation method of the fermented Sophora japonica flower extract includes the following steps: inoculating Aspergillus niger into a solid fermentation medium containing Sophora japonica flowers for fermentation to obtain a fermented product; separating the fermented product to obtain the fermented Sophora japonica flower extract. This fermented Sophora japonica flower extract can enhance the inhibitory effect of colistin on Salmonella (especially Salmonella pullorum), helping to reduce antibiotic use and combat the growth of drug resistance.

The invention discloses a method for improving colistin E wastewater treatment capacity, and belongs to the technical field of wastewater treatment. The method specifically comprises the following steps: A, putting activated sludge into a reactor; and B, taking the colistin E production wastewater additionally added with cyclic diguanylic acid to flow through the reactor at a certain organic load. The colistin E production wastewater has a multi-aspect toxic effect on microorganisms in activated sludge, so that the growth of the microorganisms is inhibited, and cyclic diguanylate is a key regulatory factor for synthesizing an extracellular matrix and can activate a series of genes participating in the synthesis of components such as exopolysaccharides and proteins, so that the microorganisms can generate a large amount of extracellular matrix, and the growth of the microorganisms is inhibited. The extracellular matrixes are main components forming the biological membrane and can provide a protective and stable living environment for microorganisms. Experiments prove that the cyclic diguanylate is additionally added into the colistin E production wastewater, so that the wastewater treatment capacity can be effectively improved.